What's Happening With Regeneron Pharmaceuticals Stock On Monday?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary endpoints.
Benzinga ·